Trial Profile
A Phase 1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs AMB 051 (Primary) ; Pembrolizumab
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; AmMax Bio
- 07 Sep 2019 Status changed from active, no longer recruiting to completed.
- 02 Aug 2019 The trial has been completed in Belgium (End date: 2019-05-17) according to European Clinical Trials Database record.
- 28 Feb 2019 The trial has been completed in Germany according to European Clinical Trials Database record.